 |
PDBsum entry 6pl2
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Type 2 inhibitor leads of human tropomyosin receptor kinase (htrka).
|
 |
|
Authors
|
 |
G.Subramanian,
S.J.Bowen,
Y.Zhu,
N.Roush,
T.Zachary,
C.Javens,
T.Williams,
A.Janssen,
A.Gonzales.
|
 |
|
Ref.
|
 |
Bioorg Med Chem Lett, 2019,
29,
126624.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
In silico virtual screening using the ligand-based ROCS approach and the
commercially purchasable compound collection from the ZINC database resulted in
the identification of distinctly different and novel acetamide core frameworks
with series representatives 1a and 2a exhibiting nanomolar affinity in the
kinase domain only hTrkA HTRF biochemical assay. Additional experimental
validation using the Caliper technology with either the active or inactive
kinase conditions demonstrated the leads, 1a and 2a, to preferentially bind the
kinase inactive state. X-ray structural analysis of the kinase domain of
hTrkA…1a/2a complexes confirmed the kinase, bind the inhibitor leads in the
inactive state and to exhibit a type 2 binding mode with the DFG-out and
αC-helix out conformation. The leads also demonstrated sub-micromolar activity
in the full length hTrkA cell-based assay and selectivity against the closely
related hTrkB isoform. However, the poor microsomal stability and permeability
of the leads is suggestive of a multiparametric lead optimization effort
requirement for further progression.
|
 |
|
|
|
|
 |